SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Silberstein SD, Lipton RB, Goadsby PJ. Headache in Clinical Practice, 2nd edn. Oxford: Martin Dunitz; 2002:53.
  • 2
    Klapper J. Divalproex sodium in migraine prophylaxis: A dose-controlled study. Cephalalgia. 1997;17:103-108.
  • 3
    Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349.
  • 4
    Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol. 2004;61:490-495.
  • 5
    Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997;17:109-112.
  • 6
    Cady RK, Mathew N, Diener H-C, Hu P, Haas M, Novak GP, Study Group. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache. 2009;49:216-226.
  • 7
    Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg. 2000;123:669-676.
  • 8
    Shuhendler AJ, Lee S, Siu M, et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: A meta-analysis of randomized, double-blind, placebo controlled trials. Pharmacotherapy. 2009;29:784-791.
  • 9
    Simpson DM, Gracies J-M, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2008;70:1691-1698.
  • 10
    Dodick DW, Aurora SK, Turkel CC, et al. Botulinum toxin type A for treatment of chronic migraine: The double blind phase of the PREEMPT clinical program. Cephalalgia. 2009;29(Suppl. 1):34. Abstract# P057.
  • 11
    Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793-803.
  • 12
    Diener H, Dodick D, Aurora S, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804-814.
  • 13
    Allergan press release. Botox® receives first authorisation in UK as preventative treatment in chronic migraine. 2010. [WWW document].URL http://agn.client.shareholder.com/releases.cfm (accessed September 9, 2010).
  • 14
    Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004;24(Suppl. 1):1-160.
  • 15
    Mathew NT, Jaffri FA. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: A pilot study. Headache. 2009;49:1466-1478.
  • 16
    Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(Suppl. 7):1-96.
  • 17
    Olesen J, Bousser MG, Diener HC, et al. (Headache Classification Committee). New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742-746.
  • 18
    Cady RK, Schreiber CP. Botulinum toxin type a as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache. 2008;48:900-913.
  • 19
    Macedo A, Baños JE, Farré M. Placebo response in the prophylaxis of migraine: A meta-analysis. Eur J Pain. 2008;12:68-75.
  • 20
    van der Kuy PH, Lohman JJ. A quantification of the placebo response in migraine prophylaxis. Cephalalgia. 2002;22:265-270.
  • 21
    Farinelli I, Coloprisco G, DeFillippis S, Martelletti P. Long-term benefits of botulinum toxin type A (Botox) in chronic daily headache: A five-year long experience. J Headache Pain. 2006;7:407-412.
  • 22
    Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the Botox® clinical migraine research group. Headache. 2000;40:445-450.
  • 23
    Aurora SK, Gawel M, Brandes JL, Pokta S, VanDenburgh AM; BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: A randomized, double-blind, placebo-controlled exploratory study. Headache. 2007;47:486-499.